GlassScriptPhysician profile
Stephen W Lacey
NPI 1316923261
$3,826.08
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,094 · 2020: $454 · 2021: $724 · 2022: $1,555.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $671.27 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $558.53 | 2019-2022 | |
| Pfizer INC. | $345.26 | 2019-2022 | |
| Janssen Biotech, INC. | $239.53 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.25 | 2019-2022 | |
| Braintree Laboratories, INC. | $219.42 | 2021-2022 | |
| Ethicon US, LLC | $193.24 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.85 | 2019-2022 | |
| Ardelyx, INC. | $157.40 | 2022 | |
| Merck Sharp & Dohme LLC | $124.09 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $123.73 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $112.92 | 2021 | |
| Intercept Pharmaceuticals, INC. | $110.27 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $85.53 | 2019-2022 | |
| Celgene Corporation | $69.90 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $61.80 | 2022 | |
| Amgen INC. | $61.66 | 2021-2022 | |
| Daiichi Sankyo INC. | $58.72 | 2019-2022 | |
| Mauna Kea Technologies, INC. | $49.15 | 2019 | |
| Organon LLC | $39.94 | 2022 | |
| Redhill Biopharma INC. | $33.45 | 2022 | |
| Alfasigma USA, INC. | $32.36 | 2020 | |
| Ucb, INC. | $31.51 | 2019-2020 | |
| Allergan, INC. | $22.93 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.83 | 2020 | |
| Romark Laboratories, Lc | $11.54 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$2,808.06 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Lacey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.